NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice

British Journal of Pharmacology

Volumn 170, Issue 2, 2013, Pages 426-439

  Zhang, Li ^a,b   Li, Ruizhao ^b   Shi, Wei ^b   Liang, Xinling ^b   Liu, Shuangxin ^b   Ye, Zhiming ^b   Yu, Chunping ^b   Chen, Yuanhan ^b   Zhang, Bin ^b   Wang, Wenjian ^b   Lai, Yuxiong ^b   Ma, Jianchao ^b   Li, Zhuo ^b   Tan, Xiaofan ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

11R VIVIT; activate nuclear factor of activated T cells; diabetic nephropathy; podocyte; uPAR

Indexed keywords

11R VIVIT; ALBUMIN; CALCINEURIN; GLUCOSE; MESSENGER RNA; PROTECTIVE AGENT; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT2; UNCLASSIFIED DRUG; UROKINASE;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL COUNT; CELL DAMAGE; CELL IMMORTALIZATION; CELL PROTECTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MECHANISM; FLUID INTAKE; FOOD INTAKE; GENE EXPRESSION; GENE SILENCING; GENETIC MODEL; GLOMERULAR FILTRATION BARRIER; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; KIDNEY MASS; LIVER WEIGHT; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; SIGNAL TRANSDUCTION;

11R-VIVIT; ACTIVATE NUCLEAR FACTOR OF ACTIVATED T-CELLS; DIABETIC NEPHROPATHY; PODOCYTE; UPAR;

ALBUMINURIA; ANIMALS; APOPTOSIS; CALCINEURIN; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GENE KNOCKDOWN TECHNIQUES; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED C57BL; NFATC TRANSCRIPTION FACTORS; OLIGOPEPTIDES; PODOCYTES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION;

EID: 84883255760     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12292     Document Type: Article

References (41)

1. Aramburu J, Garcia-Cozar F, Raghavan A, Okamura H, Rao A, Hogan PG, (1998). Selective inhibition of NFAT activation by a peptide spanning the calcineurin targeting site of NFAT. Mol Cell 1: 627-637.
2. Aramburu J, Yaffe MB, Lopez-Rodriguez C, Cantley LC, Hogan PG, Rao A, (1999). Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 285: 2129-2133.
3. Atkins RC, Zimmet P, (2010). World Kidney Day Steering Committee. Diabetic kidney disease: act now or pay later. J Am Soc Hypertens 4: 3-6.
4. Benedito AB, Lehtinen M, Massol R, Lopes UG, Kirchhausen T, Rao A, et al. (2005). The transcription factor NFAT3 mediates neuronal survival. J Biol Chem 280: 2818-2825.
5. Chin ER, Olson EN, Richardson JA, Yang Q, Humphries C, Shelton JM, et al. (1998). A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev 12: 2499-2509.
6. Choudhury D, Tuncel M, Levi M, (2010). Diabetic nephropathy, a multifaceted target of new therapies. Discov Med 10: 406-415.
7. Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR, (2012). Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 172: 761-769.
8. Cohen MP, Clements RS, Hud E, Cohen JA, Ziyadeh FN, (1996). Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy. Exp Nephrol 4: 166-171.
9. Fogo AB, (2011). The targeted podocyte. J Clin Invest 121: 2142-2145.
10. Graef IA, Chen F, Chen L, Kuo A, Crabtree GR, (2001). Signals transduced by Ca (2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 105: 863-875.
11. Ibrahim HN, Hostetter TH, (1997). Diabetic nephropathy. J Am Soc Nephrol 8: 487-493.
12. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, NC3Rs Reporting Guidelines Working Group (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
13. Larrieu D, Thiébaud P, Duplàa C, Sibon I, Thézé N, Lamazière JM, (2005). Activation of the Ca (2+) / calcineurin/NFAT2 pathway controls smooth muscle cell differentiation. Exp Cell Res 310: 166-175.
14. Li JJ, Kwak SJ, Jung DS, Kim JJ, Yoo TH, Ryu DR, et al. (2007). Podocyte biology in diabetic nephropathy. Kidney Int Suppl 106: S36-S42.
15. Li R, Zhang L, Shi W, Zhang B, Liang X, Liu S, et al. (2013). NFAT2 mediates high glucose-induced glomerular podocyte apoptosis through increased Bax expression. Exp Cell Res 319: 992-1000.
16. Li Y, Kang YS, Dai C, Kiss LP, Wen X, Liu Y, (2008). Epithelial-to- mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 172: 299-308.
17. Lin H, Sue YM, Chou Y, Cheng CF, Chang CC, Li HF, et al. (2010). Activation of a nuclear factor of activated T-lymphocyte-3(NFAT3) by oxidative stress in carboplatin-mediated renal apoptosis. Br J Pharmacol 161: 1661-1676.
18. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
19. Nijenhuis T, Sloan AJ, Hoenderop JG, Flesche J, van Goor H, Kistler AD, et al. (2011). Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol 179: 1719-1732.
20. Parving HH, Hovind P, Rossing K, Andersen S, (2001). Evolving strategies for renoprotection: diabetic nephropathy. Curr Opin Nephrol Hypertens 10: 515-522.
21. Qiu WJ, Zhou Y, Jiang L, Fang L, Chen L, Su WF, et al. (2012). Genipin inhibits mitochondrial uncoupling protein 2 expression and ameliorates podocyte injury in diabetic mice. PLoS ONE 7: e41391.
22. Ranger AM, Grusby MJ, Hodge MR, Gravallese EM, de la Brousse FC, Hoey T, et al. (1998). The transcription factor NFATc is essential for cardiac valve formation. Nature 392: 186-190.
23. Rao A, Luo C, Hogan PG, (1997). Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 15: 707-747.
24. Remuzzi G, Schieppati A, Ruggenenti P, (2002). Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 346: 1145-1151.
25. Rico M, Mukherjee A, Konieczkowski M, Bruggeman LA, Miller RT, Khan S, et al. (2005). WT1-interacting protein and ZO-1 translocate into podocyte nuclei after puromycin aminonucleoside treatment. Am J Physiol Renal Physiol 289: F431-F441.
26. Schlondorff J, Del CD, Carrasquillo R, Lacey V, Pollak MR, (2009). TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription. Am J Physiol Cell Physiol 296: C558-C569.
27. Seaquist ER, Ibrahim HN, (2010). Approach to the patient with type 2 diabetes and progressive kidney disease. J Clin Endocrinol Metab 95: 3103-3110.
28. Sharma K, McCue P, Dunn SR, (2003). Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 284: F1138-F1144.
29. Smith HW, Marshall CJ, (2010). Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11: 23-36.
30. Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, Kitoh M, et al. (2006). SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice. Am J Physiol Renal Physiol 290: F813-F820.
31. Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, et al. (2011). Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant 26: 2475-2484.
32. Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J, (2012). Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 55: 566-578.
33. Wang L, Fields TA, Pazmino K, Dai Q, Burchette JL, Howell DN, et al. (2005). Activation of Galpha q-coupled signaling pathways in glomerular podocytes promotes renal injury. J Am Soc Nephrol 16: 3611-3622.
34. Wang L, Chang JH, Paik SY, Tang Y, Eisner W, Spurney RF, (2011). Calcineurin (CN) activation promotes apoptosis of glomerular podocytes both in vitro and in vivo. Mol Endocrinol 25: 1376-1386.
35. Wang Y, Jarad G, Tripathi P, Pan M, Cunningham J, Martin DR, et al. (2010). Activation of NFAT signaling in podocytes causes glomerulosclerosis. J Am Soc Nephrol 21: 1657-1666.
36. Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, et al. (2008). Modification of kidney barrier function by the urokinase receptor. Nat Med 14: 55-63.
37. Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, et al. (2005). Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 16: 2941-2952.
38. Wolf G, Ritz E, (2003). Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol 14: 1396-1405.
39. Wolf G, Chen S, Ziyadeh FN, (2005). From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54: 1626-1634.
40. Zhang B, Shi W, Ma J, Sloan A, Faul C, Wei C, et al. (2012a). The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury. J Mol Med (Berl) 90: 1407-1420.
41. Zhang B, Xie S, Shi W, Yang Y, (2012b). Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant 27: 1746-1755.